Top

Published in:

01-07-2018 | Original Article

Evaluation of work disability in Japanese patients with rheumatoid arthritis: from the TOMORROW study

Authors: Shohei Anno, Yuko Sugioka, Kentaro Inui, Masahiro Tada, Tadashi Okano, Kenji Mamoto, Tatsuya Koike

Published in: Clinical Rheumatology | Issue 7/2018

Abstract

To evaluate work disability and associated factors in patients with rheumatoid arthritis (RA) who participated in the TOMORROW study, a 10-year cohort study in Japan. Subjects in this cross-sectional analysis comprised 191 RA patients and 191 age- and sex-matched non-RA individuals. Work-related outcomes were measured using the Work Productivity and Activity Impairment questionnaire by employment status (full-time worker (FTW), employed ≥ 35 h/week; part-time worker (PTW), < 35 h/week; home worker (HW), non-employed). In addition, we assessed the EuroQol-5 Dimensions (EQ-5D) and Health Assessment Questionnaire (HAQ) to evaluate quality of life and activities of daily living. No significant differences were evident between groups in percentages of participants in each employment status (p = 0.11), percentages of absenteeism (FTW, p = 1.00; PTW, p = 0.29), presenteeism (FTW, p = 0.23; PTW, p = 0.54), overall work impairment (FTW, p = 0.23; PTW, p = 0.73), or percentage of activity impairment (AI) (FTW, p = 0.62; PTW, p = 0.60). In the HW group, percentage of AI was higher in RA patients than that in non-RA patients (p < 0.01). Among RA patients, HW showed lower EQ-5D and higher HAQ than FTW or PTW (p < 0.001 each). Higher disease activity was observed in HW than FTW (p < 0.01). In terms of the effect of biological disease-modifying anti-rheumatic drugs, no significant differences in work-related outcomes, health status, or daily activity were evident between users and non-users. No significant differences in employment status or work impairment were seen between RA and non-RA groups among paid workers. HW with RA showed more impaired daily activity and higher disease activity compared to working RA patients. Trial registration: University Hospital Medical Information Network Clinical Trials Registry: UMIN000003876. Registered 1 Jun 2010.

Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL (2001) The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 44:2009–2017CrossRefPubMed

Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM (1999) Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 42:1854–1860CrossRefPubMed

Yelin E, Meenan R, Nevitt M, Epstein W (1980) Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med 93:551–556CrossRefPubMed

Mäkisara GL, Mäkisara P (1982) Prognosis of functional capacity and work capacity in rheumatoid arthritis. Clin Rheumatol 1:117–125CrossRefPubMed

Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK (1984) Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 27:864–872CrossRefPubMed

Sokka T, Krishnan E, Häkkinen A, Hannonen P (2003) Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis Rheum 48:59–63CrossRefPubMed

Wolfe F, Allaire S, Michaud K (2007) The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol 34:2211–2217PubMed

Allaire S, Wolfe F, Niu J, Zhang Y, Zhang B, LaValley M (2008) Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out. Arthritis Rheum 59:1082–1089CrossRefPubMedPubMedCentral

Laas K, Peltomaa R, Kautiainen H, Puolakka K, Leirisalo-Repo M (2006) Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment. Ann Rheum Dis 65:924–928CrossRefPubMed

10.

Augustsson J, Neovius M, Cullinane-Carli C, Eksborg S, van Vollenhoven RF (2010) Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry). Ann Rheum Dis 69:126–131CrossRefPubMed

11.

Osterhaus JT, Purcaru O, Richard L (2009) Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA). Arthritis Res Ther 11:R73CrossRefPubMedPubMedCentral

12.

Zhang W, Bansback N, Guh D, Li X, Nosyk B, Marra CA, Anis AH (2008) Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. J Rheumatol 35:1729–1736PubMed

13.

Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977CrossRefPubMed

14.

Burton W, Morrison A, Maclean R, Ruderman E (2006) Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond) 56:18–27CrossRef

15.

Bjork M, Thyberg I, Rikner K, Balogh I, Gerdle B (2009) Sick leave before and after diagnosis of rheumatoid arthritis—a report from the Swedish TIRA project. J Rheumatol 36:1170–1179CrossRefPubMed

16.

Hone D, Cheng A, Watson C, Huang B, Bitman B, Huang XY, Gandra SR (2013) Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States. Arthritis Care Res (Hoboken) 65:1564–1572

17.

Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRefPubMed

18.

Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis AH (2010) Validity of the work productivity and activity impairment questionnaire-general health version in patients with rheumatoid arthritis. Arthritis Res Ther 12:R177CrossRefPubMedPubMedCentral

19.

Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 4:353–365CrossRefPubMed

20.

Bruce B, Fries JF (2005) The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 23:S14–S18PubMed

21.

Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33:337–343CrossRefPubMed

22.

Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48CrossRefPubMed

23.

Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, Bombardieri S, Choi H, Combe B, Dougados M, Emery P, Gomez-Reino J, Keystone E, Koch G, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Michaud K, O'Dell J, Paulus H, Pincus T, Richards P, Simon L, Siegel J, Smolen JS, Sokka T, Strand V, Tugwell P, van der Heijde D, van Riel P, Vlad S, van Vollenhoven R, Ward M, Weinblatt M, Wells G, White B, Wolfe F, Zhang B, Zink A, Felson D, EULAR, ACR (2008) Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum 59:1371–1377CrossRefPubMed

24.

Steinbrocker O, Traeger CH, Batterman RC (1949) Therapeutic criteria in rheumatoid arthritis. JAMA 140:659–662CrossRef

25.

Braakman-Jansen LM, Taal E, Kuper IH, van de Laar MA (2012) Productivity loss due to absenteeism and presenteeism by different instruments in patients with RA and subjects without RA. Rheumatology (Oxford) 51:354–361CrossRef

26.

Kiely PD, Brown AK, Edwards CJ, O'Reilly DT, Ostör AJ, Quinn M et al (2009) Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. Rheumatology (Oxford) 48:765–772CrossRef

27.

Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3–15CrossRefPubMed

28.

Nikiphorou E, Guh D, Bansback N, Zhang W, Dixey J, Williams P, Young A (2012) Work disability rates in RA. Results from an inception cohort with 24 years follow-up. Rheumatology (Oxford) 51:385–392

29.

Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Julkunen H, Luukkainen R, Vuori K, Paimela L, Blåfield H, Hakala M, Leirisalo-Repo M (2004) Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 50:55–62CrossRefPubMed

30.

Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Hakala M, Järvinen P, Ahonen J, Forsberg S, Leirisalo-Repo M, FIN-RACo Trial Group (2005) Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 52:36–41CrossRefPubMed

31.

Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM, Walker D, Gough A, Green M, McGonagle D, Adebajo A, Jarrett S, Doherty S, Hordon L, Melsom R, Unnebrink K, Kupper H, Emery P, Yorkshire Early Arthritis Register Consortium (2008) Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 59:1467–1474CrossRefPubMed

32.

Combe B, Logeart I, Belkacemi MC, Dadoun S, Schaeverbeke T, Daurès JP, Dougados M (2015) Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort. Ann Rheum Dis 74:724–729CrossRefPubMed

33.

Kiely P, Walsh D, Williams R, Young A (2011) Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity—the early RA network (ERAN). Rheumatology (Oxford) 50:926–931

34.

van Vollenhoven RF, Cifaldi MA, Ray S, Chen N, Weisman MH (2010) Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. Arthritis Care Res (Hoboken) 62:226–234CrossRef

35.

Kavanaugh A, Han C, Bala M (2004) Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol 31:849–855PubMed

36.

Sokka T, Kautiainen H, Pincus T, Verstappen SM, Aggarwal A, Alten R et al (2010) Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther 12:R42CrossRefPubMedPubMedCentral

37.

Rantalaiho V, Kautiainen H, Korpela M, Hannonen P, Kaipiainen-Seppänen O, Möttönen T, Kauppi M, Karjalainen A, Laiho K, Laasonen L, Hakola M, Peltomaa R, Leirisalo-Repo M, NEO-RACo Study Group (2014) Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial. Ann Rheum Dis 73:1954–1961CrossRefPubMed

38.

Kessler RC, Ames M, Hymel PA, Loeppke R, McKenas DK, Richling DE et al (2004) Using the World Health Organization Health and Work Performance Questionnaire (HPQ) to evaluate the indirect workplace costs of illness. J Occup Environ Med 46:S23–S37CrossRefPubMed

39.

de Croon EM, Sluiter JK, Nijssen TF, Kammeijer M, Dijkmans BA, Lankhorst GJ et al (2005) Work ability of Dutch employees with rheumatoid arthritis. Scand J Rheumatol 34:277–283CrossRefPubMed

40.

de Croon EM, Sluiter JK, Nijssen TF, Dijkmans BA, Lankhorst GJ, Frings-Dresen MH (2004) Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 63:1362–1367CrossRefPubMedPubMedCentral

41.

Hoving JL, van Zwieten MC, van der Meer M, Sluiter JK, Frings-Dresen MH (2013) Work participation and arthritis: a systematic overview of challenges, adaptations and opportunities for interventions. Rheumatology (Oxford) 52:1254–1264

42.

Radner H, Smolen JS, Aletaha D (2014) Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther 16:R56CrossRefPubMedPubMedCentral

Title: Evaluation of work disability in Japanese patients with rheumatoid arthritis: from the TOMORROW study
Authors: Shohei Anno
Yuko Sugioka
Kentaro Inui
Masahiro Tada
Tadashi Okano
Kenji Mamoto
Tatsuya Koike
Publication date: 01-07-2018
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 7/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-018-4060-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Evaluation of work disability in Japanese patients with rheumatoid arthritis: from the TOMORROW study

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2018

Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis

Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis

Sharp decline in hydroxychloroquine dosing—analysis of 17,797 initiators from 2007 to 2016

Influence of the different “patient global assessment” formulations on disease activity score by different indices in rheumatoid arthritis

Acute fibrinous and organizing pneumonia as initial presentation of primary Sjögren’s syndrome: a case report and literature review

Resolution of femoral metaphyseal dysplasia in CINCA syndrome after long-term treatment with interleukin-1 blockade

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page